drugset / Trial / NCT04211103
Pembrolizumab in Pre Neoplastic High Grade HPV-related Vulvar and Cervical Lesions
Phase 2
Unknown
45 enrolled
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Merck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
single arm phase II trial evaluating Pembrolizumab single agent as neoadjuvant treatment before surgical conization and/or partial or radical vulvectomy in patients with pre-neoplastic cervical and vulvar high grade lesions.
Timeline
- Start
- 2020-10-14
- Primary completion
- 2024-09-01
- Completion
- 2024-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | — |